{"count": 6, "results": [{"_id": "34803555", "pmid": 34803555, "pmcid": "PMC8600156", "title": "Metformin for the management of tuberous sclerosis: What does the evidence tell us?", "journal": "EXCLI J", "authors": ["Srinivasan A", "Naga Shashi Kiran B", "Koduvath A", "Pal A", "Suresh A", "Kannan A", "Ravichandran M"], "date": "2021-09-27T00:00:00Z", "doi": "10.17179/excli2021-4213", "meta_date_publication": "2021", "meta_volume": "20", "meta_issue": "", "meta_pages": "1474-1475", "score": 50285.11, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ for the management of @<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@tuberous sclerosis@@@: What does the evidence tell us?", "citations": {"NLM": "Srinivasan A, Naga Shashi Kiran B, Koduvath A, Pal A, Suresh A, Kannan A, Ravichandran M. Metformin for the management of tuberous sclerosis: What does the evidence tell us? EXCLI J. 2021;20():1474-1475. PMID: 34803555", "BibTeX": "@article{34803555, title={Metformin for the management of tuberous sclerosis: What does the evidence tell us?}, author={Srinivasan A and Naga Shashi Kiran B and Koduvath A and Pal A and Suresh A and Kannan A and Ravichandran M}, journal={EXCLI J}, volume={20}, pages={1474-1475}}"}}, {"_id": "33681737", "pmid": 33681737, "pmcid": "PMC7910694", "title": "The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial", "journal": "EClinicalMedicine", "authors": ["Amin S", "Mallick AA", "Edwards H", "Cortina-Borja M", "Laugharne M", "Likeman M", "O'Callaghan FJK"], "date": "2021-01-14T00:00:00Z", "doi": "10.1016/j.eclinm.2020.100715", "meta_date_publication": "2021 Feb", "meta_volume": "32", "meta_issue": "", "meta_pages": "100715", "score": 50280.906, "text_hl": "The @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@tuberous sclerosis@@@ (@<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@MiTS@@@) study: A randomised double-blind placebo-controlled trial", "citations": {"NLM": "Amin S, Mallick AA, Edwards H, Cortina-Borja M, Laugharne M, Likeman M, O'Callaghan FJK. The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial EClinicalMedicine. 2021 Feb;32():100715. PMID: 33681737", "BibTeX": "@article{33681737, title={The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trial}, author={Amin S and Mallick AA and Edwards H and Cortina-Borja M and Laugharne M and Likeman M and O'Callaghan FJK}, journal={EClinicalMedicine}, volume={32}, pages={100715}}"}}, {"_id": "36833359", "pmid": 36833359, "pmcid": "PMC9957184", "title": "Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways:Case Report and Literature Review", "journal": "Genes (Basel)", "authors": ["Jurca CM", "Kozma K", "Petchesi CD", "Zaha DC", "Magyar I", "Munteanu M", "Faur L", "Jurca A", "Bembea D", "Severin E", "Jurca AD"], "date": "2023-02-08T00:00:00Z", "doi": "10.3390/genes14020433", "meta_date_publication": "2023 Feb 8", "meta_volume": "14", "meta_issue": "2", "meta_pages": "", "score": 50267.566, "text_hl": "In a multicenter randomized double-blind trial, Amin et al. administered @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ and placebo to 51 @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@tuberous sclerosis@@@ for 1 year. ", "citations": {"NLM": "Jurca CM, Kozma K, Petchesi CD, Zaha DC, Magyar I, Munteanu M, Faur L, Jurca A, Bembea D, Severin E, Jurca AD. Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways:Case Report and Literature Review Genes (Basel). 2023 Feb 8;14(2):. PMID: 36833359", "BibTeX": "@article{36833359, title={Tuberous Sclerosis, Type II Diabetes Mellitus and the PI3K/AKT/mTOR Signaling Pathways:Case Report and Literature Review}, author={Jurca CM and Kozma K and Petchesi CD and Zaha DC and Magyar I and Munteanu M and Faur L and Jurca A and Bembea D and Severin E and Jurca AD}, journal={Genes (Basel)}, volume={14}, number={2}}"}}, {"_id": "36116284", "pmid": 36116284, "title": "A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis.", "journal": "Seizure", "authors": ["Singh R", "Sarangi SC", "Singh S", "Tripathi M"], "date": "2022-10-01T00:00:00Z", "doi": "10.1016/j.seizure.2022.09.003", "meta_date_publication": "2022 Oct", "meta_volume": "101", "meta_issue": "", "meta_pages": "253-261", "score": 50258.543, "text_hl": "METHODS: Preclinical and clinical evidence involving @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@'s role in @DISEASE_Epilepsy @DISEASE_MESH:D004827 @@@epilepsy@@@ and special conditions like @<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@tuberous sclerosis@@@ have been reviewed in this paper. ", "citations": {"NLM": "Singh R, Sarangi SC, Singh S, Tripathi M. A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis. Seizure. 2022 Oct;101():253-261. PMID: 36116284", "BibTeX": "@article{36116284, title={A review on role of metformin as a potential drug for epilepsy treatment and modulation of epileptogenesis.}, author={Singh R and Sarangi SC and Singh S and Tripathi M}, journal={Seizure}, volume={101}, pages={253-261}}"}}, {"_id": "23228442", "pmid": 23228442, "title": "Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.", "journal": "Eur J Cancer", "authors": ["Yang J", "Kalogerou M", "Gallacher J", "Sampson JR", "Shen MH"], "date": "2013-04-01T00:00:00Z", "doi": "10.1016/j.ejca.2012.10.027", "meta_date_publication": "2013 Apr", "meta_volume": "49", "meta_issue": "6", "meta_pages": "1479-90", "score": 50053.06, "text_hl": "In this study, we investigated the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on @DISEASE_Kidney_Diseases @DISEASE_MESH:D007674 @@@renal lesions@@@ in a @GENE_TSC1 @GENE_64930 @@@Tsc1@@@(+/-) @SPECIES_10090 @@@mouse@@@ model of @<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@tuberous sclerosis@@@. ", "citations": {"NLM": "Yang J, Kalogerou M, Gallacher J, Sampson JR, Shen MH. Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin. Eur J Cancer. 2013 Apr;49(6):1479-90. PMID: 23228442", "BibTeX": "@article{23228442, title={Renal tumours in a Tsc1+/- mouse model show epigenetic suppression of organic cation transporters Slc22a1, Slc22a2 and Slc22a3, and do not respond to metformin.}, author={Yang J and Kalogerou M and Gallacher J and Sampson JR and Shen MH}, journal={Eur J Cancer}, volume={49}, number={6}, pages={1479-90}}"}}, {"_id": "30290005", "pmid": 30290005, "title": "The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.", "journal": "Br J Clin Pharmacol", "authors": ["Amin S", "Lux A", "O'Callaghan F"], "date": "2019-01-01T00:00:00Z", "doi": "10.1111/bcp.13780", "meta_date_publication": "2019 Jan", "meta_volume": "85", "meta_issue": "1", "meta_pages": "37-46", "score": 50052.8, "text_hl": "Because of its effect on the @GENE_MTOR @GENE_2475 @@@mTOR@@@ pathway, there may be a role for @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in slowing or reversing growth of life-threatening @DISEASE_Hamartoma @DISEASE_MESH:D006222 @@@hamartomas@@@ in @<m>DISEASE_Tuberous_Sclerosis</m> @DISEASE_MESH:D014402 @@@tuberous sclerosis complex@@@.", "citations": {"NLM": "Amin S, Lux A, O'Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol. 2019 Jan;85(1):37-46. PMID: 30290005", "BibTeX": "@article{30290005, title={The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.}, author={Amin S and Lux A and O'Callaghan F}, journal={Br J Clin Pharmacol}, volume={85}, number={1}, pages={37-46}}"}}]}